Posterior pelvic exenteration, a crucial component in the surgeon's toolbox for optimizing surgical cytoreduction for advanced ovarian cancer
- PMID: 35320890
- PMCID: PMC9024179
- DOI: 10.3802/jgo.2022.33.e41
Posterior pelvic exenteration, a crucial component in the surgeon's toolbox for optimizing surgical cytoreduction for advanced ovarian cancer
Conflict of interest statement
Outside the submitted work, Dr. Chi reports personal fees from Apyx Medical Corp., Biom 'Up and AstraZeneca, as well as stock/options of Doximity, Moderna, BioNTech SE, and Apyx Medical Corp.
Comment on
-
Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.J Gynecol Oncol. 2022 May;33(3):e31. doi: 10.3802/jgo.2022.33.e31. Epub 2022 Feb 4. J Gynecol Oncol. 2022. PMID: 35320883 Free PMC article.
References
-
- Tseng JH, Cowan RA, Zhou Q, Iasonos A, Byrne M, Polcino T, et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival? Gynecol Oncol. 2018;151:24–31. - PMC - PubMed
-
- Wallace S, Kumar A, Mc Gree M, Weaver A, Mariani A, Langstraat C, et al. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecol Oncol. 2017;145:21–26. - PubMed
-
- Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol. 2012;126:220–223. - PubMed